Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer Meeting Abstract
| Authors: | Hurvitz, S. A.; Tolaney, S. M.; Punie, K.; Loirat, D.; Oliveira, M.; Kalinsky, K.; Zelnak, A.; Aftimos, P.; Dalenc, F.; Sardesai, S.; Hamiltion, E.; Sharma, P.; Recalde, S.; Gil, E. C.; Traina, T.; O'Shaughnessy, J.; Cortés, J.; Tsai, M.; Vahdat, L.; Diéras, V.; Carey, L.; Rugo, H. S.; Goldenberg, D. M.; Hong, Q.; Olivo, M.; Itri, L. M.; Bardia, A. |
| Abstract Title: | Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer |
| Meeting Title: | 43rd Annual San Antonio Breast Cancer Symposium (2020 SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 81 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2020 Dec 8-11 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2021-02-01 |
| Language: | English |
| ACCESSION: | WOS:000618737700018 |
| PROVIDER: | wos |
| DOI: | 10.1158/1538-7445.SABCS20-GS3-06 |
| Notes: | Meeting Abstract: GS3-06 -- This symposium was held virtually due to COVID-19 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
